Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease

Brain Research

Volumn 777, Issue 1-2, 1997, Pages 153-160

  Lapchak, Paul A ^a,b   Araujo, Dalia M ^a   Hilt, Dana C ^a   Sheng, Jackie ^a   Jiao, Shoushu ^a  

^a AMGEN INC   (United States)

^b NONE   (United States)

Author keywords

6 Hydroxydopamine; Direct gene transfer; Dopamine turnover; Dopaminergic neuron; Neurodegeneration; Neurotrophic factor; Recovery; Regeneration; Substantia nigra

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; FEMALE; GENE THERAPY; GENE TRANSFER; IMMUNOCYTOCHEMISTRY; NERVE CELL DEGENERATION; NERVE REGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ADENOVIRIDAE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTORS; NERVE REGENERATION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SYMPATHOLYTICS;

EID: 0031589698     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01100-1     Document Type: Article

References (30)

1. [1] S. Akli, C. Caillaud, E. Vigne, L.D. Stratford-Perricaudet, L. Poenaru, M. Perricaudet, A. Kahn, M.R. Peschanski, Transfer of a foreign gene into the brain using adenovirus vectors, Nature Genet. 3 (1993) 224-228.
2. [2] D.M. Araujo, D.C. Hilt, P.J. Miller, D. Wen, S. Jiao, P.A. Lapchak, RET receptor tyrosine kinase immunoreactivity is altered in GDNF-responsive neurons following lesions of the nigrostriatal and septohippocampal pathways, Neuroscience 80 (1) (1997) 9-16.
3. [3] G. Bajocchi, S.H. Feldman, R.G. Crystal, A. Mastrangeli, Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors, Nature Genet. 3 (1993) 229-234.
4. [4] K.E. Bowenkamp, A.F. Hoffman, G.A. Gerhardt, M.A. Henry, P.T. Biddle, B.J. Hoffer, A.E. Granholm, Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons, J. Comp. Neurol. 355 (1995) 479-489.
5. [5] K.E. Bowenkamp, D. David, P.A. Lapchak, M.A. Henry, A.-C. Granholm, B.J. Hoffer, T.J. Mahalik, 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat: a possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor, Exp. Brain Res. 111 (1996) 1-7.
6. [6] E.K. Bowenkamp, P.A. Lapchak, B.J. Hoffer, P.J. Miller, P.C. Bickford, Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats, Exp. Neurol. 145 (1) (1997) 104-117.
7. [7] X.O. Breakefield, Gene delivery into the brain using virus vectors, Nature Genet. 3 (1993) 187-189.
8. [8] D.L. Choi-Lundberg, Q. Lin, Y-N. Chang, Y.L. Chiang, C.M. Hay, H. Mohajeri, B.L. Davidson, M.C. Bohn, Dpaminergic neurons protected from degeneration by GDNF gene therapy, Science 275 (1997) 838-841.
9. [9] D.M. Gash, Z. Zhang, A. Ovadia, W.A. Cass, A. Yi, L. Simmerman, D. Russell, D. Martin, P.A. Lapchak, F. Collins, B.J. Hoffer, G.A. Gerhardt, GDNF promotes functional recovery in parkinsonian monkeys, Nature 380 (1996) 252-255.
10. [10] A.M. Gomez-Foix, W.S. Goats, S. Baque, T. Alam, R.D. Gerald, C.B. Newgard, Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism, J. Biol. Chem. 267 (1992) 25129-25134.
11. [11] J. Herz, R.D. Gerard, Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice, Proc. Natl. Acad. Sci. USA 90 (1993) 2812-2816.
12. [12] B.J. Hoffer, A. Hoffman, K. Bowenkamp, P. Huettl, J. Hudson, D. Martin, L-F.H. Lin, G.A. Gerhardt, Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo, Neurosci. Lett. 182 (1994) 107-111.
13. [13] P. Horellou, E. Vigne, M-N. Castel, P. Barneoud, P. Colin, M. Perricaudet, P. Delaere, J. Mallet, Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease, Neuroreport 6 (1994) 49-53.
14. [14] J. Hudson, A.-C. Granholm, G.A. Gerhardt, M.A. Henry, A. Hoffman, P. Biddle, N.S. Leele, L. Mackerlova, J.D. Lile, F. Collins, B.J. Hoffer, Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo, Brain Res. Bull. 36 (1995) 425-432.
15. [15] S.S. Jiao, G. Acsadi, A. Jani, P.L. Felgner, J.A. Wolff, Persistence of plasmid DNA and expression in rat brain cells in vivo, Exp. Neurol. 115 (1992) 400-413.
16. [16] G. Karpati, H. Lochmuller, J. Nalbantoglu, H. Durham, The principles of gene therapy for the nervous system, Trends Neurosci. 19 (1996) 49-54.
17. [17] C.M. Kearns, G.M. Gash, GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo, Brain Res. 672 (1995) 104-111.
18. [18] P.A. Lapchak, P.J. Miller, F. Collins, S.S. Jiao, Glial cell line-dirived neurotrophic factor (GDNF) attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine lesioned adult rats: comparison of intraventricular and intranigral delivery, Neuroscience 78 (1997) 61-72.
19. [19] P.A. Lapchak, S.S. Jiao, F. Collins, P.J. Miller, Glial cell line-dirived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection, Brain Res. 747 (1997) 92-102.
20. [20] P.A. Lapchak, S.S. Jiao, P.J. Miller, L.R. Williams, V. Cummins, G. Inouye, C. Matheson, Q. Yan, Pharmacological characterization of glial cell line-derived neurotrophic factor: implications for GDNF as a therapeutic molecule to treat neurodegenerative diseases, Cell Tissue Res. 286 (1996) 225-233.
21. [21] P.A. Lapchak, P.J. Miller, S.S. Jiao, Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype in aged F344 rats and attenuates age-related locomotor hypofunction, Neuroscience 77 (1997) 745-752.
22. [22] P.A. Lapchak, P.J. Miller, S.S. Jiao, D.M. Araujo, D. Hilt, F. Collins, Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease, Neurodegeneration 5 (1996) 197-205.
23. [23] P.A. Lapchak, Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS, Rev. Neurosci. 7 (1996) 165-176.
24. [24] P.A. Lapchak, S. Jiao, P.J. Miller, Temporal relationship between glial cell line-derived neurotrophic factor increased hypothalamic galanin content and decreased weight gain, Neuroscience, (1997) in press.
25. [25] P.A. Lapchak, D.M. Gash, F. Collins, D. Hilt, P.J. Miller, D.M. Araujo, Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease, Exp. Neurol. 145 (1997) 309-321.
26. [26] G. Le Gal La Salle, J.J. Robert, S. Berrard, V. Ridoux, L.D. Stratford-Perricaudet, M. Perricaudet, J. Mallet, An adenovirus vector for gene transfer into neurons and glia in the brain, Science 259 (1993) 988-990.
27. [27] J. Opacka-Juffry, S. Ashworth, S.P. Hume, D. Martin, D.J. Brooks, S.B. Blunt, GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET, Neuroreport 7 (1995) 348-352.
28. [28] G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, Inc. San Diego, 1986.
29. [29] H. Sauer, C. Rosenblad, A. Bjorklund, Glial cell line-drived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion, Proc. Natl. Acad. Sci. USA 92 (1995) 8935-8939.
30. [30] M.J.A. Wood, H.M. Charlton, K.J. Wood, K. Kajiwara, A.P. Byrnes, Immune responses to adenovirus vectors in the nervous system, Trends Neurosci. 19 (1996) 497-501.